Cabot (NYSE:CBT – Get Rating) is scheduled to release its earnings data after the market closes on Monday, May 2nd. Analysts expect Cabot to post earnings of $1.40 per share for the quarter. Cabot has set its FY22 guidance at $5.50-5.90 EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.
Cabot (NYSE:CBT – Get Rating) last posted its earnings results on Monday, January 31st. The specialty chemicals company reported $1.29 EPS for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.23. Cabot had a return on equity of 28.88% and a net margin of 2.78%. The firm had revenue of $968.00 million for the quarter, compared to analysts’ expectations of $815.24 million. During the same period last year, the firm earned $1.18 EPS. On average, analysts expect Cabot to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.
NYSE:CBT opened at $67.65 on Monday. Cabot has a 52 week low of $47.59 and a 52 week high of $74.87. The company has a quick ratio of 0.80, a current ratio of 1.21 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $3.83 billion, a PE ratio of 39.56 and a beta of 1.44. The stock’s 50-day moving average price is $70.03 and its 200-day moving average price is $61.54.
In other news, SVP Hobart Kalkstein sold 11,805 shares of the business’s stock in a transaction that occurred on Wednesday, February 16th. The stock was sold at an average price of $73.50, for a total transaction of $867,667.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.78% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Amalgamated Bank raised its position in shares of Cabot by 0.4% during the 4th quarter. Amalgamated Bank now owns 40,308 shares of the specialty chemicals company’s stock valued at $2,265,000 after buying an additional 154 shares during the period. MetLife Investment Management LLC raised its position in shares of Cabot by 0.5% during the 4th quarter. MetLife Investment Management LLC now owns 47,542 shares of the specialty chemicals company’s stock valued at $2,672,000 after buying an additional 240 shares during the period. LPL Financial LLC raised its position in shares of Cabot by 15.6% during the 3rd quarter. LPL Financial LLC now owns 5,129 shares of the specialty chemicals company’s stock valued at $257,000 after buying an additional 691 shares during the period. California State Teachers Retirement System raised its position in shares of Cabot by 2.2% during the 4th quarter. California State Teachers Retirement System now owns 78,579 shares of the specialty chemicals company’s stock valued at $4,416,000 after buying an additional 1,672 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in shares of Cabot by 31.3% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 13,659 shares of the specialty chemicals company’s stock valued at $685,000 after buying an additional 3,254 shares during the period. Institutional investors and hedge funds own 90.85% of the company’s stock.
Cabot Company Profile (Get Rating)
Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through three segments: Reinforcement Materials, Performance Chemicals, and Purification Solutions. The company offers reinforcing carbons used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites.
Further Reading
- Get a free copy of the StockNews.com research report on Cabot (CBT)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.